NeuClone Pharmaceuticals has announced that its NeuCeptin (trastuzumab) proposed biosimilar to Herceptin has successfully met all of its primary and secondary endpoints in a Phase I clinical trial. NeuCeptin is “one of several biosimilars developed in partnership between NeuClone and the Serum Institute of India.”
Highlighting the “significant milestone” for the company, NeuClone’s CEO and founder Noelle Sunstrom said the positive results from the NeuCeptin trial “reflect our dedication to provide